05B4 Den, Robert B. - Thomas Jefferson University - Thomas Jefferson University

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  2. Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti's Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. Eur Urol 2016;70:588–96
  3. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy
  4. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome
  5. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer
  6. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  7. The landscape of prognostic outlier genes in high-risk prostate cancer
  8. Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities
  9. Dosing, administration, and safety of radium-223: How i do it
  10. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer
  11. Novel targeted siRNA-loaded hybrid nanoparticles: Preparation, characterization and in vitro evaluation
  12. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data
  13. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis
  14. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  15. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  16. Uncertainties encountered in implementation of adaptive planning with in vivo dosimeters
  17. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  18. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes
  19. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
  20. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes